

## C-Path's Lysosomal Disease Consortium Welcomes Chiesi Group as its Newest Member

**TUCSON, Ariz., July 23, 2024** — Critical Path Institute's (C-Path) Critical Path for Lysosomal Diseases (CPLD) Consortium today proudly announced the addition of Chiesi Group as a member. Chiesi Group is an international, research-focused biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The partnership marks a significant milestone in the Consortium's mission to accelerate drug development for lysosomal diseases (LDs) and improve the lives of individuals affected by these rare conditions.

"We are pleased to join the CPLD Consortium and take part in this important collaborative effort to help address the significant unmet medical needs affecting people living with LDs," said Giacomo Chiesi, MBA, head of Chiesi Global Rare Diseases.

"Driven by our deep commitment to advancing sustainable therapeutic options for rare diseases including LDs, we look forward to working closely with the Consortium to support innovation and progress in LD drug development."



LDs are rare inherited disorders characterized by enzyme deficiencies crucial for breaking down specific molecules within the body's cells. The absence of these enzymes leads to the accumulation of harmful substances, resulting in cellular dysfunction and tissue damage, particularly in the brain and nervous system. "Current treatments for LDs aim to replace missing enzymes, reduce harmful substance buildup, or utilize gene therapy," said Krista Casazza, Ph.D., Scientific Director of CPLD Consortium. "However, the complexity and diversity of LDs present challenges in developing effective treatments, compounded by the lack of standardized measures to track disease progression across the 70+ LD subtypes."

The CPLD Consortium serves as a dynamic public-private partnership dedicated to addressing these challenges and accelerating LD drug development. By bringing together leading experts from academia, industry, and regulatory agencies, the Consortium aims to drive innovation, establish standardized approaches for measuring disease progression, and facilitate the development of new therapies for LDs.

"We are delighted to welcome Chiesi as the newest member of the CPLD Consortium," said Amanda Klein, Pharm.D., Executive Director of CPLD Consortium. "Their dedication to scientific excellence aligns perfectly with the CPLD Consortium's vision of fostering collaboration and innovation in LD drug development globally. Their expertise and unique perspective will undoubtedly enrich our collaborative efforts and propel us forward in our shared mission. Together, we are poised to make significant strides towards advancing LD drug development and improving the lives of those affected by LDs."



For more information about CPLD consortium, please visit <https://c-path.org/>.

**About Critical Path Institute**

Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the [FDA's Critical Path Initiative](#). **C-Path's mission is to lead collaborations that advance better treatments for people worldwide.** Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit [c-path.org](http://c-path.org).

*Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 54% funded by the FDA/HHS, totaling \$19,436,549, and 46% funded by non-government source(s), totaling \$16,373,368. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.*

## About Chiesi Group

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment.

By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi's commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we're part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With over 85 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group's research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For further information please visit [www.chiesi.com](http://www.chiesi.com).

## Contacts:

Roxan Triolo Olivas  
C-Path  
520.954.1634  
[rolivas@c-path.org](mailto:rolivas@c-path.org)

Kissy Black  
C-Path  
615.310.1894  
[kblack@c-path.org](mailto:kblack@c-path.org)